Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Non Operating Income: 2015-2025

Historic Other Non Operating Income for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to $2.8 million.

  • Seres Therapeutics' Other Non Operating Income rose 112.62% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 205.44%. This contributed to the annual value of -$14.1 million for FY2024, which is 10627.61% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Other Non Operating Income is $2.8 million, which was down 33.85% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Other Non Operating Income ranged from a high of $7.1 million in Q1 2025 and a low of -$22.5 million during Q3 2024.
  • Moreover, its 3-year median value for Other Non Operating Income was $999,000 (2023), whereas its average is $81,727.
  • In the last 5 years, Seres Therapeutics' Other Non Operating Income surged by 3,127.27% in 2023 and then tumbled by 2,353.95% in 2024.
  • Over the past 5 years, Seres Therapeutics' Other Non Operating Income (Quarterly) stood at -$316,000 in 2021, then soared by 92.72% to -$23,000 in 2022, then skyrocketed by 1,560.87% to $336,000 in 2023, then soared by 2,006.25% to $7.1 million in 2024, then soared by 112.62% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $4.3 million for Q2 2025, and $7.1 million during Q1 2025.